Current approach in the treatment of hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

605

HTML

8887

Figures (1-3)

140

Tables (1-1)

168

Sum=9800

Sep 15, 2010 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastrointest Oncol. Sep 15, 2010; 2(9): 348-359
Published online Sep 15, 2010. doi: 10.4251/wjgo.v2.i9.348

Figure 1 Hepatocancerogenesis. MAPK: Mitogen-activated protein kinase; P13k: Phosphatidylinositol 3-kinase.

Figure 2 In sorafenib group median survival is 2. 8 mo longer than placebo group (HR = 0.69, P = 0.0006)[71].

Figure 3 Algorithm for treatment of hepatocellular carcinoma.

Citation: Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2010; 2(9): 348-359
URL: https://www.wjgnet.com/1948-5204/full/v2/i9/348.htm
DOI: https://dx.doi.org/10.4251/wjgo.v2.i9.348